KPTI - NASDAQ
Karyopharm Therapeutics Inc.
$9.07
+3.0%Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
At a Glance
Live Snapshotkpti
Net Cash Provided by Financing Activities
Last Annual Value
30.05M
3-Year CAGR
-46%
5-Year CAGR
-29%
10-Year CAGR
-11%
Karyopharm Therapeutics Inc. Competitors Analysis of Net Cash Provided by Financing Activities
| Company | Net Cash Provided by Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Karyopharm Therapeutics Inc. NASDAQ:KPTI | 30.05M | 199.0% | -16.4% | -5.2% | |
 Telomir Pharmaceuticals, Inc. Common Stock NASDAQ:TELO | 9.71M | 36.0% | 141.0% | N/A | |
 Senti Biosciences, Inc. NASDAQ:SNTI | 53.73M | 310.1% | -4.7% | N/A | |
 BioAtla, Inc. NASDAQ:BCAB | 9.51M | 398.0% | -32.8% | N/A | |
 Actinium Pharmaceuticals, Inc. AMEX:ATNM | 29.32M | 25.4% | -3.6% | 6.4% | |
 Aligos Therapeutics, Inc. NASDAQ:ALGS | 101.64M | 4.8% | 5.3% | N/A | |
 INmune Bio, Inc. NASDAQ:INMB | 18.21M | N/A | -28.3% | 44.8% | |
 Mersana Therapeutics, Inc. NASDAQ:MRSN | 4.09M | -64.9% | -42.2% | -23.3% | |
 CEL-SCI Corporation AMEX:CVM | 19.51M | 60.8% | -18.6% | -0.4% | |
 X4 Pharmaceuticals, Inc. NASDAQ:XFOR | 238.63M | 39.2% | 26.3% | 29.4% |
Karyopharm Therapeutics Inc. Fair Value Envelope
Related Guides
Continue your KPTI research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.